Citations

Clear

9383 citation(s) found for "Thomas, PS".

A pleiotropic recurrent dominant ITPR3 variant causes a complex multisystemic disease
Molitor, Anne , Lederle, Alexandre , Radosavljevic, Mirjana , Sapuru, Vinay , Thomas, Megan E. Zavorka, Yang, Jianying , Shirin, Mahsa , Collin-Bund, Virginie , Jeřábková, Kateřina , Miao, Zhichao , Bernard, Alice , Grenot, Pierre , Lewis, Elyssa G., Person, Richard, Esperón-Moldes, Uxía-Saraiva, Kaare, Milja, Nokelainen, Pekka, Batzir, Nurit Assia , Hoffer, Gal Zaks, Stemmelen, Tristan , Naegely, Lydie , Hanauer, Antoine , Bibi‐Triki, Sabrina , Grün, Sarah, Jung, Sophie , Busnelli, Ignacio, Tripolszki, Kornélia , Ordoñez, Natalia, Song, Eunkyung , Zajo, Kristin , Partida‐Sánchez, Santiago , Robledo‐Avila, Frank , Kumánovics, Attila , Pichot, Angélique , Toker, Ori , Mejía, César , Parvaneh, Nima , Knapp, Esther , Hersh, Joseph H., Kenney, Heather , Bajwa, Rajinder , Thomas, Caroline , Ehl, Stephan , Isidor, Bertrand , Abraham, Roshini S. , Hite, Richard K. , Bertoli‐Avella, Aida M. , Bahram, Seiamak , Zavorka Thomas, Megan E , Jerabkova-Roda, Katerina , Rolli, Véronique , Grenot, Pierre , Castro, Carla Noemi , Rosenzwajg, Michelle , Person, Richard , Batzir, Nurit Assia , Hoffer, Gal Zaks , Paul, Nicodème , Stemmelen, Tristan , Naegely, Lydie , Hanauer, Antoine , Bibi-Triki, Sabrina , Jung, Sophie , Bauer, Peter , Zajo, Kristin , Partida-Sanchez, Santiago , Robledo-Avila, Frank , Kumanovics, Attila , Louzoun, Yoram , Hirschler, Aurélie , Pichot, Angélique , Toker, Ori , Mejía, Cesar Andrés Muñoz , Parvaneh, Nima , Knapp, Esther , Delmonte, Ottavia M , Notarangelo, Luigi D , Goetz, Jacky G , Kahwash, Samir B , Carapito, Christine , Bajwa, Rajinder P S , Thomas, Caroline , Ehl, Stephan , Isidor, Bertrand , Carapito, Raphael , Abraham, Roshini S , Hite, Richard K , Bahram, Seiamak , Esperón-Moldes, Uxia , Al‐Ali, Ruslan , Kenney, Heather , Kahwash, Samir B. , Marcus, Nufar

Mayo Clinic

Science Advances | September 13, 2024 | Volume: 10 | Issue: 37 | Pages: No page available

10.1126/sciadv.ado5545 | PMID 39270020 Get It

Inositol 1,4,5-trisphosphate (IP3) receptor type 1 ( ITPR1 ), 2 ( ITPR2 ), and 3 ( ITPR3 ) encode the IP3 receptor (IP3R), a key player in intracellular calcium release. In four unrelated patients, we report that an identical ITPR3 de novo variant—NM_002224.3:c.7570C>T, p.Arg2524Cys—causes, through a dominant-negative effect, a complex multisystemic disorder with immunodeficiency. This leads to defective calcium homeostasis, mitochondrial malfunction, CD4 + lymphopenia, a quasi-absence of naïve CD4 + and CD8 + cells, an increase in memory cells, and a distinct TCR repertoire. The calcium defect was recapitulated in Jurkat knock-in. Site-directed mutagenesis displayed the exquisite sensitivity of Arg 2524 to any amino acid change. Despite the fact that all patients had severe immunodeficiency, they also displayed variable multisystemic involvements, including ectodermal dysplasia, Charcot-Marie-Tooth disease, short stature, and bone marrow failure. In conclusion, unlike previously reported ITPR1-3 deficiencies leading to narrow, mainly neurological phenotypes, a recurrent dominant ITPR3 variant leads to a multisystemic disease, defining a unique role for IP3R3 in the tetrameric IP3R complex.
TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Gessain, Grégoire , Anzali, Ahmed-Amine , Lerousseau, Marvin , Mulder, Kevin , Bied, Mathilde , Aupérin, Anne , Stockholm, Daniel , Signolle, Nicolas , Sassi, Farah , Costa, Maria Eugénia Marques Da , Sayadi, Alexandre , Weidner, Daniela , Blampey, Quentin , Nakkireddy, Sumanth Reddy , Dutertre, Charles‐Antoine , Walter, Thomas , Marhic, Alix , Guerlain, Joanne , Casiraghi, Odile , Marques Da Costa, Maria Eugenia , Marchais, Antonin , Sayadi, Alexandre , Weidner, Daniela , Uderhardt, Stefan , Blampey, Quentin , Nakkireddy, Sumanth Reddy , Broutin, Sophie , Dutertre, Charles-Antoine , Busson, Pierre , Walter, Thomas , Marhic, Alix , Moya-Plana, Antoine , Guerlain, Johanne , Breuskin, Ingrid , Casiraghi, Odile , Gorphe, Philippe , Classe, Marion , Scoazec, Jean-Yves , Blériot, Camille , Ginhoux, Florent , Auperin, Anne , Uderhardt, Stefan , Moya‐Plana, Antoine

Mayo Clinic

Cancer Discovery | September 13, 2024 | Volume: 14 | Issue: 12 | Pages: 2352-2366

10.1158/2159-8290.cd-24-0018 | PMID 39270324 Get It

Abstract Patients with head and neck squamous cell carcinomas (HNSCC) often have poor outcomes due to suboptimal risk management and treatment strategies; yet integrating novel prognostic biomarkers into clinical practice is challenging. Here, we report the presence of multinucleated giant cells (MGC)—a type of macrophages—in tumors from patients with HNSCC, which are associated with a favorable prognosis in treatment-naive and preoperative chemotherapy–treated patients. Importantly, MGC density increased in tumors following preoperative therapy, suggesting a role of these cells in the antitumoral response. To enable clinical translation of MGC density as a prognostic marker, we developed a deep-learning model to automate its quantification on routinely stained pathological whole slide images. Finally, we used spatial transcriptomic and proteomic approaches to describe the MGC-related tumor microenvironment and observed an increase in central memory CD4 T cells. We defined an MGC-specific signature resembling to TREM2-expressing mononuclear tumor-associated macrophages, which colocalized in keratin tumor niches. Significance: Novel individual biomarkers are needed to guide therapeutic decisions for patients with head and neck cancer. We report for the first time, granulomas of TREM2-expressing multinucleated giant macrophages in keratin-rich tumor niches, as a biomarker of favorable prognosis and developed a deep-learning model to automate its quantification on routinely stained pathological slides.
Structural and Functional Characterization of the Most Frequent Pathogenic PRKN Substitution p.R275W
Bustillos, Bernardo A. , Cocker, Liam T. , Coban, Matt , Weber, Caleb A., Bredenberg, Jenny M., Boneski, Paige K, Siuda, Joanna , Puschmann, Andreas , Narendra, Derek P. , Wszołek, Zbigniew K. , Ross, Owen A. , Caulfield, Thomas R. , Springer, Wolfdieter , Fiesel, Fabienne C. , Wszolek, Z.K. , Coban, Mathew A , Puschmann, Andreas , Narendra, Derek P , Caulfield, Thomas R , Springer, Wolfdieter , Fiesel, Fabienne C , Ross, Owen A , Siuda, Joanna S. , Sławek, Jarosław , Graff, Caroline , Dickson, Dennis W.

Mayo Clinic

Cells | September 13, 2024 | Volume: 13 | Issue: 18 | Pages: 1540

10.3390/cells13181540 | PMID 39329724 Get It

Mutations in the PINK1 and PRKN genes are the most frequent genetic cause of early-onset Parkinson disease. The pathogenic p.R275W substitution in PRKN is the most frequent substitution observed in patients, and thus far has been characterized mostly through overexpression models that suggest a possible gain of toxic misfunction. However, its effects under endogenous conditions are largely unknown. We used patient fibroblasts, isogenic neurons, and post-mortem human brain samples from carriers with and without PRKN p.R275W to assess functional impact. Immunoblot analysis and immunofluorescence were used to study mitophagy activation, and mitophagy execution was analyzed by flow cytometry of the reporter mitoKeima. The functional analysis was accompanied by structural investigation of PRKN p.R275W. We observed lower PRKN protein in fibroblasts with compound heterozygous p.R275W mutations. Isogenic neurons showed an allele-dose dependent decrease in PRKN protein. Lower PRKN protein levels were accompanied by diminished phosphorylated ubiquitin and decreased MFN2 modification. Mitochondrial degradation was also allele-dose dependently impaired. Consistently, PRKN protein levels were drastically reduced in human brain samples from p.R275W carriers. Finally, structural simulations showed significant changes in the closed form of PRKN p.R275W. Our data suggest that under endogenous conditions the p.R275W mutation results in a loss-of-function by destabilizing PRKN.
Discharge instruction comprehension by older adults in the emergency department: A systematic review and meta‐analysis
Mulqueen, Sydney, Carreras‐Tartak, Jossie, Gettel, Cameron J. , Schonberg, Mara A. , Carpenter, Christopher R. , Liu, Shan W. , Haimovich, Adrian D , Gettel, Cameron , Carpenter, Christopher R , Liu, Shan W , Thomas, Stephen H , Hastings, Susan N. , Thomas, Stephen H.

Mayo Clinic

Academic Emergency Medicine | September 12, 2024 | Volume: 31 | Issue: 11 | Pages: 1165-1172

10.1111/acem.15013 | PMID 39264024 Get It

AbstractIntroductionOlder adults are at high risk of adverse health outcomes in the post–emergency department (ED) discharge period. Prior work has shown that discharged older adults have variable understanding of their discharge instructions which may contribute to these outcomes. To identify discharge comprehension gaps amenable to future interventions, we utilize meta‐analysis to determine patient comprehension across five domains of discharge instructions: diagnosis, medications, self‐care, routine follow‐up, and return precautions.MethodsUsing Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, two reviewers sourced evidence from databases including Medline (PubMed), EMBASE, Web of Science, CINAHL, and Google Scholar (for gray literature). Publications or preprints appearing before April 2024 were included if they focused on geriatric ED discharge instructions and reported a proportion of patients with comprehension of at least one of five predefined discharge components. Meta‐analysis of eligible studies for each component was executed using random‐effects modeling to describe the proportion of geriatric ED cases understanding the discharge instructions; where appropriate we calculated pooled estimates, reported as percentages with 95% confidence interval (CI).ResultsOf initial records returned (N = 2898), exclusions based on title or abstract assessment left 51 studies for full‐text review; of these, seven constituted the study set. Acceptable heterogeneity and absence of indication of publication bias supported pooled estimates for proportions comprehending instructions on medications (41%, 95% CI 31%–50%, I2 = 43%), self‐care (81%, 95% CI 76%–85%, I2 = 43%), and routine follow‐up (76%, 95% CI 72%–79%, I2 = 25%). Key findings included marked heterogeneity with respect to comprehending two discharge parameters: diagnosis (I2 = 73%) and return precautions (I2 = 95%).ConclusionsOlder patients discharged from the ED had greater comprehension of self‐care and follow‐up instructions than about their medications. These findings suggest that medication instructions may be a priority domain for future interventions.
Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs
Jin, Yunjung , Li, Fuyao , Li, Zonghua , Ikezu, Tadafumi C. , O’Leary, Justin , Selvaraj, Manikandan , Zhu, Yiyang , Martens, Yuka A. , Koga, Shunsuke , Santhakumar, Hannah , Li, Yonghe , Lü, Wenyan, You, Yang , Lolo, Kiara , DeTure, Michael , Davis, Mary Dabney , McLean, Pamela J. , Ross, Owen A. , Kanekiyo, Takahisa , Zhao, Na , Beasley, Alexandra I , Davis, Mary D , McLean, Pamela J , Ross, Owen A , Kanekiyo, Takahisa , Ikezu, Tsuneya , Caulfield, Thomas R , Carr, Jonathan , Wszolek, Z.K. , Bu, Guojun , Dickson, Dennis W , Zhao, Na , Koga, Shunsuke , Li, Zonghua , Li, Fuyao , Yang, You , Soto‐Beasley, Alexandra I. , Ikezu, Tsuneya , Caulfield, Thomas R. , Carr, Jonathan , Wszołek, Zbigniew K. , Bu, Guojun , Dickson, Dennis W.

Mayo Clinic

Science Advances | September 11, 2024 | Volume: 10 | Issue: 37 | Pages: No page available

10.1126/sciadv.adk3700 | PMID 39259788 Get It

Aggregated α-synuclein (α-SYN) proteins, encoded by the SNCA gene, are hallmarks of Lewy body disease (LBD), affecting multiple brain regions. However, the specific mechanisms underlying α-SYN pathology in cortical neurons, crucial for LBD-associated dementia, remain unclear. Here, we recapitulated α-SYN pathologies in human induced pluripotent stem cells (iPSCs)–derived cortical organoids generated from patients with LBD with SNCA gene triplication. Single-cell RNA sequencing, combined with functional and molecular validation, identified synaptic and mitochondrial dysfunction in excitatory neurons exhibiting high expression of the SNCA gene, aligning with observations in the cortex of autopsy-confirmed LBD human brains. Furthermore, we screened 1280 Food and Drug Administration–approved drugs and identified four candidates (entacapone, tolcapone, phenazopyridine hydrochloride, and zalcitabine) that inhibited α-SYN seeding activity in real-time quaking-induced conversion assays with human brains, reduced α-SYN aggregation, and alleviated mitochondrial dysfunction in SNCA triplication organoids and excitatory neurons. Our findings establish human cortical LBD models and suggest potential therapeutic drugs targeting α-SYN aggregation for LBD.
Overview of ADNI MRI
Jack, Clifford R. , Arani, Arvin , Borowski, Bret, Crawford, Karen , DeCarli, Charles , Fletcher, Evan, Fox, Nick C. , Gunter, Jeffrey L. , Ittyerah, Ranjit, Harvey, Danielle , Jahanshad, Neda , Maillard, Pauline , Malone, Ian B., Reyes, Denise A., Thomas, David L. , Thompson, Paul M., Tosun, Duygu , Ward, Chadwick P., Weiner, Michael W., Initiative, Alzheimer's Disease Neuroimaging, DeCarli, Charles , Malone, Ian B. , Borowski, Bret J, Jack, Clifford R , Arani, Arvin , Fox, Nick C , Harvey, Danielle J , Tosun, Duygu , Maillard, Pauline , Cash, David M. , Das, Sandhitsu R. , Nir, Talia M. , Reid, Robert I. , Schwarz, Christopher G. , Senjem, Matthew L. , Thompson, Paul M. , Yushkevich, Paul A. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | September 11, 2024 | Volume: 20 | Issue: 10 | Pages: 7350-7360

10.1002/alz.14166 | PMID 39258539 Get It

Abstract The magnetic resonance imaging (MRI) Core has been operating since Alzheimer's Disease Neuroimaging Initiative's (ADNI) inception, providing 20 years of data including reliable, multi‐platform standardized protocols, carefully curated image data, and quantitative measures provided by expert investigators. The overarching purposes of the MRI Core include: (1) optimizing and standardizing MRI acquisition methods, which have been adopted by many multicenter studies and trials worldwide and (2) providing curated images and numeric summary values from relevant MRI sequences/contrasts to the scientific community. Over time, ADNI MRI has become increasingly complex. To remain technically current, the ADNI MRI protocol has changed substantially over the past two decades. The ADNI 4 protocol contains nine different imaging types (e.g., three dimensional [3D] T1‐weighted and fluid‐attenuated inversion recovery [FLAIR]). Our view is that the ADNI MRI data are a greatly underutilized resource. The purpose of this paper is to educate the scientific community on ADNI MRI methods and content to promote greater awareness, accessibility, and use. Highlights The MRI Core provides multi‐platform standardized protocols, carefully curated image data, and quantitative analysis by expert groups. The ADNI MRI protocol has undergone major changes over the past two decades to remain technically current. As of April 25, 2024, the following numbers of image series are available: 17,141 3D T1w; 6877 FLAIR; 3140 T2/PD; 6623 GRE; 3237 dMRI; 2846 ASL; 2968 TF‐fMRI; and 2861 HighResHippo (see Table 1 for abbreviations). As of April 25, 2024, the following numbers of quantitative analyses are available: FreeSurfer 10,997; BSI 6120; tensor based morphometry (TBM) and TBM‐SYN 12,019; WMH 9944; dMRI 1913; ASL 925; TF‐fMRI NFQ 2992; and medial temporal subregion volumes 2726 (see Table 4 for abbreviations). ADNI MRI is an underutilized resource that could be more useful to the research community.
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
Abro, Brooj , Maurer, Matthew J. , Burack, Richard , Chapman, Jennifer R. , Cohen, Jonathon B. , Friedberg, Jonathan W. , Inghirami, Giorgio , Lossos, Izidore S. , Martin, Peter W., McDonnell, Timothy J. , Riska, Shaun M., Flowers, Christopher R. , Burack, W Richard , Cohen, Jonathon B , Inghirami, Giorgio , Link, Brian K , Lossos, Izidore S , Nastoupil, Loretta J , Vega, Francisco , Cerhan, James R , Feldman, Andrew L , Maurer, Matthew , Habermann, Thomas M. , Kahl, Brad S. , Larson, Melissa C. , Link, Brian K. , Martin, Peter, Nastoupil, Loretta J. , Syrbu, Sergei , Vega, Francisco , Vij, Kiran R , Cerhan, James R. , Jaye, David L. , Feldman, Andrew L.

Mayo Clinic

Blood | September 10, 2024 | Volume: 144 | Issue: 19 | Pages: 2063-2066

10.1182/blood.2024025681 | PMID 39255410 Get It

Abstract Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will affect <1% of non-Hodgkin lymphomas.
Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery
Ganz, Patricia A. , Cecchini, Reena S. , White, Julia , Vicini, Frank A. , Arthur, Douglas W., Rabinovitch, Rachel , Kuske, Robert R. , Julian, Thomas B. , Parda, David S., Scheier, Michael F. , Winter, Kathryn, Paik, Soonmyung , Kuerer, Henry M. , Vallow, Laura A., Pierce, Lori J. , Mamounas, Eleftherios P. , Germain, Isabelle, Gustafson, Gregory S, Grossheim, Linda , Petersen, Ivy A. , Curran, Walter J. , White, Julia R , Hudes, Richard S , Wolmark, Norman , Mamounas, Eleftherios P. , McCormick, Beryl L. , Bear, Harry D. , Wolmark, Norman

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 10, 2024 | Volume: 117 | Issue: 1 | Pages: 103-111

10.1093/jnci/djae219 | PMID 39254630 Get It

Abstract Background NRG Oncology NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was quality of life (QOL). Methods The QOL sub-study used validated self-report questionnaires, including the Breast Cancer Treatment Outcome Scale (BCTOS) and the 36-Item Short Form Health Survey (SF-36) vitality scale. Assessments occurred before random assignment, at treatment completion (chemotherapy or radiotherapy), 4 weeks later, at 6, 12, 24, and 36 months. Primary aims: cosmesis change equivalency (baseline to 3 years; a priori margin of equivalence 0.4 standard deviations) and fatigue change superiority (baseline to end of treatment [EOT]) for APBI vs WBI, by patient groups treated with or without chemotherapy when appropriate. Results From March 21, 2005 to May 25, 2009, 975 patients enrolled in this sub-study; 950 had follow-up data. APBI had 3-year cosmesis equivalent to WBI (95% CI = -0.0001 to -0.16; equivalence margin -0.22 to -0.22) in all patients. The APBI group without chemotherapy had less EOT fatigue (P = .011; mean score APBI 63 vs WBI 59); the APBI group receiving chemotherapy had worse EOT fatigue (P = .011; APBI 43 vs WBI 49). The APBI group reported less pain (BCTOS) at EOT (WBI 2.29 vs APBI 1.97) but worse pain at 3 years (WBI 1.62 vs APBI 1.71). APBI patients reported greater convenience of care than with WBI and reported less symptom severity at EOT and 4 weeks later. Conclusion Cosmetic outcomes were similar for the APBI and WBI groups, with small statistically significant differences in other outcomes that varied over time. Differences in fatigue and other symptoms appeared to resolve by ≥6 months. APBI may be preferred by some patients, for whom extended treatment is burdensome. ClinicalTrials.gov NCT00103181.
Endoscopic, Endonasal, Transsphenoidal, Transclival Approach for Resection of Odontoid Process: 2-Dimensional Operative Video
Zervos, Thomas M. , Cho, Steve S. , Samiappan, Sathish Prabu Sathyamangalam , Little, Andrew S. , Santarelli, Griffin D., Ronecker, Jennifer S., McClendon, Jamal, Sathyamangalam Samiappan, Sathish Prabu

Mayo Clinic

Operative Neurosurgery | September 9, 2024 | Volume: 28 | Issue: 1 | Pages: 132-132

10.1227/ons.0000000000001350 | PMID 39248517 Get It

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
Gandhi, Pranav , Lalla, Anjana, Singh, Rashmi B. Halker , McAllister, Peter , Smith, Jonathan H., Dabruzzo, Brett , Chalermpalanupap, Natty, Kelton, Kari , Halker Singh, Rashmi B , Ailani, Jessica , Lalla, Anjana, Nahas, Stephanie J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 9, 2024 | Volume: 64 | Issue: 10 | Pages: 1253-1263

10.1111/head.14824 | PMID 39248007 Get It

Abstract Objective To estimate the number needed to treat and cost per additional responder for atogepant and rimegepant versus placebo for the preventive treatment of episodic migraine (EM) in the United States. Background Migraine has an enormous impact on a person's daily activities and quality of life, and results in significant clinical and economic burden to both individuals and society. It is important to understand the comparative efficacy and economic value of oral calcitonin gene–related peptide receptor antagonists (gepants) for preventive treatment of EM. Currently, atogepant and rimegepant are US Food and Drug Administration approved for preventive treatment of migraine (rimegepant for EM and atogepant for EM and for chronic migraine). In the absence of head‐to‐head trials, we utilized an indirect treatment comparison on efficacy data from clinical trials conducted for the preventive treatment of EM. We estimated number needed to treat, a valuable metric used in clinical practice to compare treatment efficacy, and cost per additional responder, which can be used to establish the cost effectiveness of a treatment. Methods An indirect treatment comparison was conducted to compare the efficacy of atogepant 60 mg once daily and rimegepant 75 mg once every other day as preventive treatments for EM using published data from the registrational trials of atogepant (ADVANCE) and rimegepant (BHV3000‐305). The efficacy outcome of interest was ≥50% reduction from baseline in mean monthly migraine/headache days (≥50% responder rate), which was variably defined for a base case and two scenario analyses. Number needed to treat and cost per additional responder versus placebo were calculated and compared between both treatments (weeks 9–12 in the base case analysis; weeks 1–12 and 9–12 for atogepant and during weeks 9–12 for rimegepant in the scenario analyses). Results In the base case analysis, ≥50% responder rates were 64.9% (95% confidence interval [CI], 53.9–74.5) for atogepant and 51.8% (95% CI, 42.9–60.6) for rimegepant, compared to 44.1% (95% CI, 39.4–49.0) for placebo. The median number needed to treat versus placebo in the base case scenario was 4.8 (95% CI, 3.1–9.0) for atogepant compared to 13.0 (95% CI, 5.9–75.1) for rimegepant. The cost per additional responder versus placebo in the base case scenario was estimated to be $15,823 (95% CI, $11,079–$29,516) for atogepant compared to $73,029 (95% CI, $32,901–$422,104) for rimegepant. Results of the two scenario analyses were consistent with the base case analysis. Conclusions Atogepant had substantially lower numbers needed to treat and costs per additional responder versus placebo than rimegepant for the preventive treatment of EM across all evaluated scenarios. These analyses suggest that atogepant may be more cost effective than rimegepant for the preventive treatment of EM. Limitations include differences in inclusion/exclusion criteria and in reporting of the ≥50% responder rates between trials.